Health · Hardware
Fortitude Biomedicines
Fortitude Biomedicines is a Waltham, Massachusetts biotech that launched in early 2026 with $13M in seed financing to develop next-generation antibody-based therapies for autoimmune diseases and cancer. Its proprietary GLUE-DAC platform bolts molecular glue degraders onto antibody-drug conjugates, aiming to use catalytic targeted protein degradation to widen the therapeutic window of ADCs and overcome the resistance that has dogged the field. Its lead program, FORT-202, is a first-in-class T-cell targeting bispecific antibody for axial spondyloarthritis expected to reach the clinic in the first half of 2027.